Varicose Veins: When Should Treatment Be on the Table?

"The veins do bulge, but do I really need treatment?"

It is the question most people ask after a diagnosis of varicose veins. The symptoms are not unbearable, so waiting seems reasonable, yet there is also the worry of letting things get worse.

What helps here is not being told to hurry into surgery, but knowing the criteria on which the decision rests. Which symptoms is treatment meant to relieve? Has the skin or tissue changed? Does the abnormality found on testing explain the problem?

In this article, "actively discussing treatment" does not mean setting a surgery date. It means weighing, in concrete terms, the benefit and risk of treatment, the scope for conservative management, and the life the patient wants to lead.

1. When recurring symptoms limit daily life

If you have to sit down part-way through standing, or have cut back on activities because of aching and heaviness, that change belongs in the consultation. Beyond "does it hurt", the important information is "what have you stopped being able to do".

The UK NICE guideline (CG168) lists varicose veins with troublesome symptoms, such as pain, discomfort, swelling, heaviness and itching, as a reason for referral to a vascular service. Recurrent varicose veins are included as well as new ones. Recommending specialist assessment is not the same as recommending surgery for everyone.

The 2025 guideline of the Society for Cardiovascular Angiography and Interventions (SCAI) suggests, for patients with symptomatic great saphenous reflux, with or without small saphenous reflux, ablation combined with conservative management rather than conservative management alone. It is a GRADE-based guideline, so each recommendation carries its own strength and certainty of evidence, and the intent is that expected benefit and burden are weighed for each patient.

The essential premise is the cause of the symptoms. Leg pain alone, or reflux on ultrasound alone, does not prove the two are connected. Examination and testing should also consider other causes (Chung & Heo, J Chest Surg 2024 review). Deciding in advance which symptoms treatment is expected to relieve also makes the result easier to judge afterwards. Why the 0.5-second reflux cut-off is a threshold, not a measure of severity, is covered in a separate column.

2. If swelling persists, confirm the cause, then discuss treatment

Swelling is easy for patients to notice, but hard to pin to a single cause.

The ESVS 2022 guideline recommends that, in patients with oedema (CEAP clinical class C3), non-venous causes of oedema be considered before treatment is planned. Where a venous abnormality and another cause of swelling coexist, treating the vein may not remove all of the swelling.

So the sequence must never be "swollen, therefore surgery". When the swelling began, whether it is one-sided or both, whether another condition or medication is involved, and how much the reflux explains, all need to be established. Where a venous contribution is confirmed, the benefit of compression and of intervention can then be compared. Why swelling can remain after treatment is explained in the C3 oedema column.

3. When the skin around the ankle is changing

Brown pigmentation around the ankle or lower shin, recurring eczema, or skin and subcutaneous tissue that is becoming hard, all need to be assessed for their cause.

The ESVS 2022 guideline recommends intervention to correct venous insufficiency in C4–C6 patients whose skin changes or ulceration are due to superficial venous incompetence. The key condition is "due to venous disease". Itching or discolouration alone does not settle the cause. Skin findings and venous testing must be judged together.

Related: Unexplained dermatitis — could the veins be the problem?

4. When there is a venous ulcer, or a healed ulcer returns

A venous ulcer is a wound in the skin that fails to heal. The wound itself needs care, and the underlying venous problem needs assessment.

This is one area where a randomised trial has compared timing directly. The EVRA trial, published in the NEJM in 2018, randomised 450 patients with venous leg ulcers at 20 UK centres. Both groups received compression; one had endovenous ablation of superficial reflux within two weeks of randomisation, the other deferred ablation until the ulcer had healed or, if it had not, until six months.

Outcome	Early ablation	Deferred ablation
Median time to ulcer healing	56 days	82 days
Ulcer healed at 24 weeks	85.6%	76.3%

Ulcers healed faster in the early-ablation group. This must not be stretched into "all varicose veins should be treated quickly". The results apply to patients who already had a venous ulcer and met the trial's entry criteria. Complications of ablation, including pain and deep vein thrombosis, were also reported.

NICE lists both a venous ulcer below the knee that has not healed within two weeks and a previously healed venous ulcer as reasons for vascular referral. The "two weeks" is not an instruction to wait once a wound has appeared.

5. When superficial vein thrombosis or bleeding from a varicose vein occurs

A firm, painful cord along a vein should be assessed for superficial vein thrombosis. Whether there is an acute clot problem is established first, and the appropriate treatment decided. This situation should not be handled in the same order as a routine consultation about varicose vein surgery. The 2023 SVS/AVF/AVLS guideline (Part II) recommends anticoagulation for superficial vein thrombosis of the main saphenous trunks. Why superficial thrombosis should not be taken lightly is set out with numbers in the clot column.

The same applies to bleeding from a varicose vein. NICE recommends immediate referral to a vascular service, and the SVS/AVF/AVLS guideline advises controlling the bleeding with leg elevation and direct pressure, then evaluating and treating the superficial venous incompetence. Even when bleeding has stopped, the cause and the risk of recurrence need assessment.

"Active treatment" here does not necessarily mean immediate vein ablation. Controlling the bleeding and establishing the location and extent of the clot, that is, dealing safely with the problem at hand, come first.

If I can bear the pain, should I keep waiting?

Whether to treat is not decided on pain intensity alone. Impact on daily life, test results, skin change and the patient's own preferences are considered together.

The 2023 SVS/AVF/AVLS guideline (Part II, recommendation 2.1.4) recommends against requiring a routine three-month trial of compression before intervention in symptomatic patients who are candidates for endovenous treatment and want it. It is a weak recommendation (Grade 2) on moderate evidence (Level B). This does not mean compression is unnecessary; it means there is insufficient basis for imposing the same waiting period on everyone.

Conversely, for asymptomatic C2 varicose veins, the same guideline's consensus statement (5.2.1) records that prophylactic intervention to prevent future deterioration "does not prevent progression of the disease". Weight control, compression stockings and avoiding prolonged standing may help, according to that statement. A visible vein alone is not a reason to rush into treatment.

The case that must be told apart: sudden swelling and pain in one leg

Everything above concerns chronic symptoms and treatment decisions. If one leg suddenly becomes swollen, painful or warm, prompt assessment is needed to check for deep vein thrombosis, among other things. Having had varicose veins before is no reason to dismiss it as the usual discomfort.

Leg pain and swelling together with sudden breathlessness or chest pain call for immediate evaluation through emergency services because of the possibility of pulmonary embolism. This is not a situation to hold for a booked vein consultation.

What da Re-Fit Clinic wants to establish before deciding on treatment

Patients deserve more than "this can be treated".

• Which symptom is most troublesome now, and how much does it limit daily life?
• How much of that symptom and skin change does venous disease explain?
• What is expected to improve with treatment, and what may remain?
• Is conservative management or observation an option?
• What are the side effects and the recovery burden?

Once these are answered, the timing and extent of treatment become clearer. Anxiety about insurance, or the name of a particular procedure, should not stand in for that judgement.

When you come in, start with when the discomfort began, which activities make it worse and what you have had to give up. da Re-Fit Clinic will put that account alongside the examination and ultrasound findings and explain whether treatment is needed and which options are open. The options themselves are compared in the treatment overview, and the practical path for overseas patients in Your treatment journey in Korea.

---

References and scope of the evidence

The recommendations above are drawn from international clinical guidelines and trials. They do not represent the reimbursement or admission criteria of any national or private insurer. Individual diagnosis and treatment are decided after examination and testing.

• NICE. Varicose veins: diagnosis and management. Clinical guideline CG168. 2013. — referral criteria: symptomatic varicose veins, skin changes, superficial vein thrombosis, active or healed venous ulcer, bleeding. https://www.nice.org.uk/guidance/cg168
• Attaran RR, Edwards ML, Arena FJ, et al. 2025 SCAI Clinical Practice Guidelines for the Management of Chronic Venous Disease. J Soc Cardiovasc Angiogr Interv. 2025;4(8):103729. (PMID: 41019905) — GRADE-based; nine recommendations across eight clinical scenarios.
• Chung JH, Heo S. Varicose Veins and the Diagnosis of Chronic Venous Disease in the Lower Extremities. J Chest Surg. 2024;57(2):109-119. (PMID: 37994090) — review of symptom assessment and diagnostic criteria; not a randomised trial of treatment.
• De Maeseneer MG, Kakkos SK, Aherne T, et al. European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. Eur J Vasc Endovasc Surg. 2022;63(2):184-267. (PMID: 35027279) — non-venous causes of oedema; treatment in skin change and ulceration.
• Gohel MS, Heatley F, Liu X, et al. A Randomized Trial of Early Endovenous Ablation in Venous Ulceration. N Engl J Med. 2018;378(22):2105-2114. (PMID: 29688123) — EVRA trial, 450 patients.
• Gloviczki P, Lawrence PF, Wasan SM, et al. The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II. J Vasc Surg Venous Lymphat Disord. 2024;12(1):101670. (PMID: 37652254) — compression trial before intervention (2.1.4), asymptomatic C2 consensus (5.2.1), superficial vein thrombosis and bleeding.
• NHS. DVT (deep vein thrombosis) — public health-service guidance on emergency symptoms. https://www.nhs.uk/conditions/deep-vein-thrombosis-dvt/